Lexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on Thursday

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Lexeo Therapeutics to post earnings of ($0.80) per share for the quarter.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.09. On average, analysts expect Lexeo Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Lexeo Therapeutics Stock Performance

Shares of Lexeo Therapeutics stock traded down $1.20 during trading on Tuesday, hitting $3.25. 1,762,261 shares of the company's stock were exchanged, compared to its average volume of 445,252. The stock has a market capitalization of $107.89 million, a price-to-earnings ratio of -1.03 and a beta of 1.27. The business has a 50-day simple moving average of $3.04 and a 200-day simple moving average of $5.32. Lexeo Therapeutics has a 52-week low of $1.45 and a 52-week high of $19.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95.

Wall Street Analysts Forecast Growth

LXEO has been the subject of several analyst reports. Leerink Partners decreased their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a report on Monday, March 24th. Chardan Capital dropped their price objective on shares of Lexeo Therapeutics from $25.00 to $22.00 and set a "buy" rating on the stock in a research note on Tuesday, April 8th. Royal Bank of Canada decreased their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. Finally, HC Wainwright restated a "buy" rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, April 8th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $22.20.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.